Literature DB >> 18214993

The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules.

Payal N Gandhi1, Xinglong Wang, Xiongwei Zhu, Shu G Chen, Amy L Wilson-Delfosse.   

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the leading cause of genetically inherited Parkinson's disease (PD). Although this multidomain protein has been shown to have both GTPase and kinase activities through the Roc and MAPKKK domains, respectively, the protein-protein interactions and pathways involved in LRRK2-mediated signaling remain elusive. Utilizing a combination of protein pull-down assays, mass spectrometry, Western blotting, and immunofluorescence microscopy, this study identifies and describes the interaction between LRRK2 and microtubules. The Roc or GTPase-like domain of LRRK2 is sufficient for interaction with alpha/beta-tubulin heterodimers. This interaction occurs in a guanine nucleotide-independent manner, suggesting that tubulin might not be an effector of the LRRK2 GTPase domain. The R1441C pathogenic mutation, located within the Roc domain, retains interaction with alpha/beta-tubulin heterodimers, suggesting that disruption of this interaction likely is not the mechanism whereby the R1441C mutation leads to disease. At a subcellular level, endogenous LRRK2 protein was found to colocalize with alpha/beta-tubulin in primary hippocampal neurons. These findings are significant in that they link LRRK2 with microtubules, a structural component of the cell that is critically involved in the pathogenesis of several neurodegenerative diseases, including PD. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18214993      PMCID: PMC2586915          DOI: 10.1002/jnr.21622

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  44 in total

1.  LRRK2 mutations in Parkinson disease.

Authors:  M Farrer; J Stone; I F Mata; S Lincoln; J Kachergus; M Hulihan; K J Strain; D M Maraganore
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra.

Authors:  Maher A Noureddine; Yi-Ju Li; Joelle M van der Walt; Robert Walters; Rita M Jewett; Hong Xu; Tianyuan Wang; Jeffrey W Walter; Burton L Scott; Christine Hulette; Don Schmechel; Judith E Stenger; Fred Dietrich; Jeffery M Vance; Michael A Hauser
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

3.  The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor.

Authors:  Graziella Cappelletti; Thomas Surrey; Rosalba Maci
Journal:  FEBS Lett       Date:  2005-08-29       Impact factor: 4.124

4.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

Review 5.  The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia.

Authors:  G Benitez-King; G Ramírez-Rodríguez; L Ortíz; I Meza
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-12

Review 6.  Molecular pathophysiology of Parkinson's disease.

Authors:  Darren J Moore; Andrew B West; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Neurosci       Date:  2005       Impact factor: 12.449

7.  The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases.

Authors:  Dena Hernandez; Coro Paisan Ruiz; Anthony Crawley; Roneil Malkani; John Werner; Katrina Gwinn-Hardy; Dennis Dickson; Fabienne Wavrant Devrieze; John Hardy; Andrew Singleton
Journal:  Neurosci Lett       Date:  2005-12-09       Impact factor: 3.046

8.  Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes.

Authors:  E Grünblatt; S Mandel; J Jacob-Hirsch; S Zeligson; N Amariglo; G Rechavi; J Li; R Ravid; W Roggendorf; P Riederer; M B H Youdim
Journal:  J Neural Transm (Vienna)       Date:  2004-09-30       Impact factor: 3.575

9.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.

Authors:  Naheed L Khan; Shushant Jain; John M Lynch; Nicola Pavese; Patrick Abou-Sleiman; Janice L Holton; Daniel G Healy; William P Gilks; Mary G Sweeney; Milan Ganguly; Vaneesha Gibbons; Sonia Gandhi; Jenny Vaughan; Louise H Eunson; Regina Katzenschlager; Juliet Gayton; Graham Lennox; Tamas Revesz; David Nicholl; Kailash P Bhatia; Niall Quinn; David Brooks; Andrew J Lees; Mary B Davis; Paola Piccini; Andrew B Singleton; Nicholas W Wood
Journal:  Brain       Date:  2005-11-04       Impact factor: 13.501

10.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.

Authors:  S Goldwurm; A Di Fonzo; E J Simons; C F Rohé; M Zini; M Canesi; S Tesei; A Zecchinelli; A Antonini; C Mariani; N Meucci; G Sacilotto; F Sironi; G Salani; J Ferreira; H F Chien; E Fabrizio; N Vanacore; A Dalla Libera; F Stocchi; C Diroma; P Lamberti; C Sampaio; G Meco; E Barbosa; A M Bertoli-Avella; G J Breedveld; B A Oostra; G Pezzoli; V Bonifati
Journal:  J Med Genet       Date:  2005-11       Impact factor: 6.318

View more
  76 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

2.  LRRK2 function on actin and microtubule dynamics in Parkinson disease.

Authors:  Loukia Parisiadou; Huaibin Cai
Journal:  Commun Integr Biol       Date:  2010-09

3.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.

Authors:  José M Bravo-San Pedro; Mireia Niso-Santano; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Ana Aiastui-Pujana; Ana Gorostidi; Vicente Climent; Rakel López de Maturana; Rosario Sanchez-Pernaute; Adolfo López de Munain; José M Fuentes; Rosa A González-Polo
Journal:  Cell Mol Life Sci       Date:  2012-07-08       Impact factor: 9.261

4.  A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.

Authors:  Andrea Meixner; Karsten Boldt; Marleen Van Troys; Manor Askenazi; Christian J Gloeckner; Matthias Bauer; Jarrod A Marto; Christophe Ampe; Norbert Kinkl; Marius Ueffing
Journal:  Mol Cell Proteomics       Date:  2010-09-27       Impact factor: 5.911

5.  Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?

Authors:  Joanna M Biernacka; Sebastian M Armasu; Julie M Cunningham; J Eric Ahlskog; Sun Ju Chung; Demetrius M Maraganore
Journal:  Parkinsonism Relat Disord       Date:  2011-08-03       Impact factor: 4.891

Review 6.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

7.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

8.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect.

Authors:  Donglai Sheng; Dianbo Qu; Ken Hon Hung Kwok; Seok Shin Ng; Adrian Yin Ming Lim; Sharon Siqi Aw; Charlie Wah Heng Lee; Wing Kin Sung; Eng King Tan; Thomas Lufkin; Suresh Jesuthasan; Mathavan Sinnakaruppan; Jianjun Liu
Journal:  PLoS Genet       Date:  2010-04-22       Impact factor: 5.917

10.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.